TABLE 3

Treatment outcome and conversion rates of culture-confirmed multidrug-resistant tuberculosis (MDR-TB) patients exposed to bedaquiline-containing regimens and treatment outcomes of MDR-TB patients starting their treatment with bedaquiline-containing regimens before December 31, 2014

Bedaquiline-containing regimenBedaquiline-containing regimen started before December 31, 2014
Patients n428130
Sputum smear conversion 30 days206/324 (63.6)
Sputum culture conversion 30 days117/389 (30.1)
Sputum smear conversion 60 days257/317 (81.1)
Sputum culture conversion 60 days213/376 (56.7)
Sputum smear conversion 90 days265/310 (85.5)
Sputum culture conversion 90 days298/370 (80.5)
Sputum smear conversion at the end of treatment126/140 (90.0)
Sputum culture conversion at the end of treatment191/208 (91.8)
Time to sputum smear conversion days4 (30–60)
Time to sputum culture conversion days60 (33–90)
Treatment outcome
 Success176/247 (71.3)100/130 (76.9)
 Cure154/247 (62.4)86/130 (66.2)
 Completion22/247 (8.9)14/130 (10.8)
 Death33/247 (13.4)8/130 (6.2)
 Default18/247 (7.3)6/130 (4.6)
 Failure19/247 (7.7)16/130 (12.3)
 Transfer out1/247 (0.4)
Duration of treatment after MDR-TB diagnosis months18 (10–22)
Body weight at end of treatment kg61.9±13.9
  • Data are presented as n/N (%), median (interquartile range) or mean±sd, unless otherwise stated.